Sawin C T, Hershman J M, Chopra I J
J Clin Endocrinol Metab. 1977 Feb;44(2):273-8. doi: 10.1210/jcem-44-2-273.
The effect of graded increments of chronically administered oral T4 or T3 on the TSH response to TRH was studied in normal young adult men. The TSH response was assessed in the baseline state and after each increment of each hormone (two weeks at each dose level) using both 30 mug and 500 mug doses of TRH. Each thyroid hormone caused a dose-related decrease in the TSH response to TRH; thus the TSH response could be used as a bioassay for the biologic activity of the thyroid hormones in man. The dose of thyroid hormone that caused a 50% suppression of the TSH response, or the SD50, was not different with either 30 mug or 500 mug of TRH indicating that thyroid hormone suppression of the TSH response is not more easily detected with a small dose of TRH. The mean SD50 for T4 was 115 mug/day, for T3 stopped 2 h before testing the mean SD50 was 29 mug/day, and for T3 stopped 24 h before testing it was 45 mug/day. Using the average SD50 for the two T3 regimens (37 mug/day), the calculated relative potency indicates that oral T3 is 3.3 times as potent as oral T4, a value in reasonable agreement with the value previously estimated with a calorigenic end-point. The mean dose of T4 needed to decrease the TSH response to TRH to below the normal range (max delta TSH of 2 muU/ml) was 150 mug/day; this value is probably more appropriate than the SD50 in the treatment of patients with primary hypothyroidism or goiter and was about the same (160 mug/day) using a peak TSH after TRH of 3 muU/ml as an end-point. Estimation of the SD50 in each subject showed a 2- to 3-fold range with all regimens of thyroid hormones; similarly there was a 2-fold in the dose of T4 needed to suppress the TSH response to TRH to below the normal range. Further, the difference in the mean SD50 for the two T3 regimens indicates that a single daily dose of oral T3 does not exert a constant biologic effect throughout the day. Thus, because of individual variation and, in the case of T3, because of changing activity during the day a given dose of thyroid hormone may have a widely varying biologic effect. There was also a 3-fold range in the relative potency of T3 to T4 in the four subjects treated with both hormones. This suggests that the therapeutic administration of a fixed ratio fo T3 to T4 may have a variable effect from patient to patient. Finally, the serum T4 rose while the serum T3 did not at a dose of T4 that abolished the TSH response to TRH, indicating that circulating T4 is a determinant of TSH secretion in normal man.
在正常年轻成年男性中,研究了长期口服甲状腺素(T4)或三碘甲状腺原氨酸(T3)的分级增量对促甲状腺激素(TSH)对促甲状腺激素释放激素(TRH)反应的影响。在基线状态以及每种激素每次增量后(每个剂量水平维持两周),使用30微克和500微克剂量的TRH评估TSH反应。每种甲状腺激素均导致TSH对TRH的反应呈剂量相关性降低;因此,TSH反应可作为人体甲状腺激素生物活性的生物测定方法。导致TSH反应被抑制50%的甲状腺激素剂量,即半效抑制剂量(SD50),在使用30微克或500微克TRH时并无差异,这表明小剂量TRH并不更容易检测到甲状腺激素对TSH反应的抑制作用。T4的平均SD50为115微克/天,T3在测试前2小时停药时的平均SD50为29微克/天,在测试前24小时停药时为45微克/天。使用两种T3给药方案的平均SD50(37微克/天)计算得出的相对效价表明,口服T3的效力是口服T4的3.3倍,该值与先前用产热终点估计的值相当一致。将TSH对TRH的反应降低至正常范围以下(最大TSH变化量为2微单位/毫升)所需的T4平均剂量为150微克/天;在治疗原发性甲状腺功能减退症或甲状腺肿患者时,该值可能比SD50更合适,并且以TRH后TSH峰值为3微单位/毫升作为终点时,该值约为160微克/天。对每个受试者的SD50进行估计显示,所有甲状腺激素给药方案的范围为2至3倍;同样,将TSH对TRH的反应抑制至正常范围以下所需的T4剂量也有2倍的差异。此外,两种T3给药方案的平均SD50差异表明,口服T3的单日剂量在一天中并未发挥恒定的生物学效应。因此,由于个体差异,以及就T3而言由于一天中活性的变化,给定剂量的甲状腺激素可能具有广泛不同的生物学效应。在接受两种激素治疗的四名受试者中,T3与T4的相对效价范围也为3倍。这表明,以固定比例的T3与T4进行治疗给药,不同患者的效果可能会有所不同。最后,在T4剂量使TSH对TRH的反应消失时,血清T4升高而血清T3未升高,这表明循环中的T[4]是正常男性TSH分泌的决定因素。